Effects of oral conjugated estrogen in preventing bleeding from renal biopsy in uremic patients

Not Applicable

• Conditions: Renal failure.; Acute renal failure, unspecified

• Registration Number: IRCT201201028593N1
• Lead Sponsor: Research Deputy of Ahvaz University of Medical Science and Health science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with renal insufficiency (creatinine greater than 3 mg/dL) who are candidates for biopsy
Exclusion criteria:
1.Pregnant women, or women who suspect pregnancy and ways to avoid becoming pregnant to leave have
2.Lactating women
3.Patients with a history of thromboembolism
4.Any of the patients treated with anticoagulant or platelet aggregation inhibitors such as warfarin, heparin, enoxaparin, Ticlopidine, clopidogrel, and statins and their agents can not be stopped
5.Patients who are treated with NSAIDs and their agents can not be interrupted for any reason
6.Patientswho have clotting disorders (such as patients with hemophilia) or in the laboratory of PT> 14, PTT> 35, or INR> 1.5
7.Patients who were under a regime of hard power (such as prolonged fasting or water treatment) and lack of essential Elements, vitamins such as vitamin C or K in the body there
8.Patients who have blood pressure higher than 160/100,before the biopsy
9.Patients with a creatinine level is less than 3 milligrams per deciliter
10.Patients who are suffering from liver cirrhosis.
11.Patients with platelet count less than 100,000
12.Patients who have cysts in both kidney
13.Patients who have undergone kidney transplant
14.Patients who are diagnosed with breast cancer
15.Patients who have a history of stroke and myocardial infarction
16.Patients who are unexplained uterine bleeding
17.Patients who have a history of sensitivity to estrogen compounds

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemodynamic change. Timepoint: Day of biopsy and next day. Method of measurement: Blood pressure and pulse rate control and orthostatic change.;Hemoglobin level. Timepoint: One day before biopsy and every 8 time after biopsy for 24 hour. Method of measurement: Hemoglobin level control.;Hematuria. Timepoint: Day of biopsy and next day. Method of measurement: Urine Analysis.;Biopsy site hematoma. Timepoint: Day of biopsy and next day. Method of measurement: Ultrasound.;Bleeding Time. Timepoint: Day of biopsy and next day. Method of measurement: Bleeding Time test with lancet.

Secondary Outcome Measures

Name	Time	Method
Major bleeding. Timepoint: Day of biopsy and next day. Method of measurement: Hemodynamic change,The need for blood transfusion,Surgery.